Key clinical point: Study supports evidence that selected corticosteroid inhalers lower pneumonia risk in COPD patients.
Major finding: Budesonide/formoterol users had a 17% lower risk of severe pneumonia than that of fluticasone propionate/salmeterol users.
Study details: Retrospective cohort study of 42,393 COPD patients new to ICS/LABA from 2011 to 2015 using national claims data from in Taiwan.
Disclosures: The Taiwan Ministry of Science and Technology provided partial support for the study. Ting-Yu Chang, MS, and colleagues have no relationships to disclose.
Chang TY et al. CHEST. 2020;157:117-29.